

1 **High seroprevalence of Immunoglobulin G (IgG) and**  
2 **IgM antibodies to SARS-CoV-2 in asymptomatic and**  
3 **symptomatic individuals amidst vaccination roll-out**  
4 **in western Kenya**

5 Shehu Shagari Awandu<sup>1,2\*</sup>, Alfred Ochieng<sup>2</sup>, Benson Onyango<sup>2</sup>, Richard Odongo  
6 Magwanga<sup>2,3</sup>, Pamela Were<sup>2</sup>, Angeline Ochung<sup>2</sup>, Fredrick Okumu<sup>2</sup>, Marceline Adhiambo  
7 Oloo<sup>2</sup>, Jim Seth Katieno<sup>3</sup>, Shirley Lidechi<sup>3</sup>, Fredrick Ogutu<sup>4</sup>, Dorothy Awuor<sup>2</sup>, Joy Nyangasi  
8 Kirungu<sup>5</sup>, Francis Orata Omoto<sup>6</sup>, Justine Midega<sup>4</sup>, Bonface Oure<sup>4</sup>, Regina Nyunja<sup>2</sup>, Eric M O  
9 Muok<sup>3</sup>, Steven Munga<sup>3</sup>, Benson Estambale<sup>2</sup>

10 <sup>1</sup>School of Health Sciences, Jaramogi Oginga Odinga University of Science and Technology,  
11 P.O Box 210-40601, Bondo-Kenya

12 <sup>2</sup>School of Biological, Physical, Mathematics and Actuarial Sciences, Jaramogi Oginga  
13 Odinga University of Science and Technology, Bondo-Kenya

14 <sup>3</sup>State Key Laboratory of Cotton Biology/Institute of Cotton Research, Chinese Academy of  
15 Agricultural Science, Anyang, Henan, China

16 <sup>4</sup>Kenya Medical Research Institute Centre for Global Health Research (CGHR), Kisumu,  
17 Kenya

18 <sup>5</sup>Kenya Industrial Research and Development Institute (KIRDI), Kenya

19 <sup>6</sup>Masinde Muliro University of Science and Technology (MMUST), Kenya

20 **\* Corresponding authors**

21 Shehu Shagari Awandu

22 E-mail: sawandu@jooust.ac.ke

23 Benson Estambale

24 Email: bestambale@jooust.ac.ke

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

## 26 **Abstract**

### 27 Background

28 The population's antibody response is a key factor in comprehending SARS-CoV-2  
29 epidemiology. This is especially important in African settings where COVID-19 impact,  
30 and vaccination rates are relatively low. This study aimed at characterizing the  
31 Immunoglobulin G (IgG) and Immunoglobulin M (IgM) in both SARS-CoV-2  
32 asymptomatic and symptomatic individuals in Kisumu and Siaya counties in Western  
33 Kenya using enzyme linked immunosorbent assays.

### 34 Results

35 The IgG and IgM overall seroprevalence in 98 symptomatic and asymptomatic  
36 individuals in western Kenya between December 2021-March 2022 was 76.5% (95%  
37 CI =66.9-84.5) and 31.6% (95% CI =22.6- 41.8) respectively. In terms of gender,  
38 males had slightly higher IgG positivity 87.8% (36/41) than females 68.4% (39/57).  
39 Amidst the ongoing vaccination roll-out during the study period, over half of the study  
40 participants (55.1%, 95% CI= 44.7-65.2) had not received any vaccine. About one  
41 third, (30.6%, 95% CI= 21.7-40.7) of the study participants had been fully vaccinated,  
42 with close to a quarter (14.3% 95% CI=8.04-22.8) partially vaccinated. When  
43 considering the vaccination status and seroprevalence, out of the 30 fully vaccinated  
44 individuals, IgG seropositivity was 86.7% (95% CI =69.3-96.2) and IgM seropositivity  
45 was 40% (95% CI =22.7-59.4). Out of the participants that had not been vaccinated at  
46 all, IgG seroprevalence was 70.3% (95% CI 56.4-82.0) with 20.4% (95% CI 10.6-33.5)  
47 seropositivity of IgM antibodies. SARs-CoV-2 PCR positivity did not significantly  
48 predict IgG ( $p = 0.457$  [95% CI 0.514- 4.371]) and IgM ( $p = 0.858$  [95% CI 0.350-  
49 2.395]) positivity.

### 50 Conclusion

51 Our data indicate a high seroprevalence of antibodies to SARS-CoV-2 in western  
52 Kenya. This suggests larger fraction of the population were infected with SARS-CoV-  
53 2 within the defined period than what PCR testing could cover.

54

## 55 Introduction

56 The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome  
57 coronavirus 2 (SARS-CoV-2), has infected more than half a billion people globally (1). The  
58 COVID-19 pandemic continues to disrupt lives, increase mortality in people with underlying  
59 co-morbidities and severely impact world economies (2). While all continents have been  
60 severely impacted, Africa has registered low scores on major metrics including mortality rates,  
61 number of cases and absence of exponential growth as predicted (3). However, the reasons  
62 for this are still unclear. Exposure of the population to many infectious diseases in the  
63 continent, generating cross reactive protective antibodies is suggested as contributing to  
64 reduced severity to the infection (3-5).

65 The SARS-CoV-2 infection is associated with the development of a robust humoral immune  
66 response with variable levels of Immunoglobulin A (IgA), IgM and IgG isotypes as the infection  
67 progresses (6, 7). Upon SARS-CoV-2 infection, the IgM response is quick and short-lived,  
68 detectable up to 20 days post infection and then wanes (7, 8). In contrast, the IgG antibody  
69 responses peak after 25 days, and are more long lived and detectable up to 120 days post  
70 symptom onset (7, 8).

71 The kinetics of anti-SARS-CoV-2 especially IgG and IgM have been profiled in several  
72 epidemiological settings in Kenya (9). Whilst an earlier study among blood donors found an  
73 overall IgG seroprevalence of 4.3 % peaking in 35-44 year olds (10), in contrast a study among  
74 community health workers reported 20.8% seroprevalence (11). More recently, a population  
75 survey in Nairobi recorded a 34.7% seroprevalence (12). Majority of studies in Kenya thus far  
76 have mainly focused on the most at-risk population in both urban and rural areas of the  
77 country. The differences in seroprevalence makes it unclear whether the antibody response  
78 to SARS-CoV-2 in western Kenya, ravaged by a host of infectious diseases including malaria,  
79 HIV and tuberculosis is similar to the rest of the country (13).

80

81 Here, we examined the levels of IgM and IgG antibodies to SARS-CoV-2 in asymptomatic and  
82 symptomatic individuals amidst vaccination roll-out, in Kisumu and Siaya counties in western  
83 Kenya. We hypothesized that in western Kenyan populations burdened by several other  
84 infectious diseases, the COVID-19 antibody responses are not different in vaccinated and  
85 non-vaccinated individuals.

## 86 **Materials and Methods**

### 87 **Study design and participants**

88 We screened and recruited individuals presenting to Kisumu and Siaya Counties referral  
89 hospitals for routine COVID-19 tests in western Kenya (Fig 1). All patients, regardless of  
90 COVID-19 symptoms were eligible for enrollment. Study procedures were explained to them,  
91 and an informed consent form signed by the participants. A detailed personal history and  
92 physical examination were carried out by the study doctor and documented on a predesigned  
93 form. Demographic data including age, gender, county of residence, symptoms, date of onset,  
94 severity, vaccination status and test type (PCR or antigen test), whether initial or follow-  
95 up/repeat.

96 **Fig 1. Map of the study site in Siaya and Kisumu counties, Kenya showing the sample**  
97 **collection points.**

### 98 **Sample size calculations**

99 Sample size was calculated in an online platform <http://www.raosoft.com/samplesize.html> ,  
100 using a margin of error of 9.78% and with a 95% confidence interval with a 50% response  
101 distribution, giving at least 96 samples.

102

### 103 **Sample collections**

104 Participants provided stool and nasopharyngeal samples in viral transport media (AB Medical  
105 Inc). Additionally, participants provided a 5 ml venous blood sample, in sterile EDTA tubes,

106 that was centrifuged to separate plasma and buffy coat. All the samples were transported  
107 under cold chain to Kenya Medical Research Institute, Centre for Global Health Research  
108 (CGHR).

## 109 **Laboratory assays**

### 110 **Enzyme linked immunosorbent assay (ELISA)**

111 To detect the presence of IgG and IgM antibodies against SARS-CoV-2 S proteins  
112 respectively, serological assays were performed using the qualitative indirect SCoV-  
113 2 Detect™ IgG ELISA kit and SCoV-2 Detect™ IgM ELISA kit (InBios International, Seattle,  
114 USA). Briefly, 50 µL each of serum samples, positive, negative and cut-off controls in  
115 duplicates were added into the SCoV-2 Antigen coated microtiter ELISA plates. The plates  
116 were covered with parafilm and incubated at 37°C for 1 hour in an incubator. The plates were  
117 subsequently washed 6 times using 300 µL of 1X Wash Buffer. 50 µL of conjugate was then  
118 added to the wells, plate covered with parafilm and incubated at 37°C for 30 minutes in an  
119 incubator. The plates were washed 6 times using 300 µL of 1X wash buffer. 75 µL of Liquid  
120 TMB substrate was added into all wells and the uncovered plates incubated at room  
121 temperature in the dark for 20 minutes. Finally, 50 µL of stop solution was added per well and  
122 the plates incubated at room temperature for 1 minute. The plates were read on a BIOTEK  
123 ELX 800 absorbance microplate reader at 450 nm optical density. The raw optical densities  
124 (ODs) were recorded, and ratios computed. Samples with IgG or IgM ratio greater than or  
125 equal to 1.1 considered positive and IgG or IgM ratio less than or equal to 0.9 considered  
126 negative.

### 127 **RNA Extraction and COVID-19 PCR tests**

128 Total nucleic acid from Nasopharyngeal samples in Viral Transport Medium (VTM) were  
129 extracted using QIAamp Viral RNA Kit (Qiagen) following manufacturer's instructions. The  
130 extracted RNA from the samples was stored at -20°C awaiting SARS-CoV-2 RT-PCR.

131 Real Time PCR was conducted using a DaAn Gene nucleic acid extraction kit (DaAn Gene  
132 Co, Ltd., of Sun Yat-sen University, China) as per manufacturer's instructions. The master mix  
133 was prepared by mixing 17  $\mu$ l of NC (ORF1ab/N) PCR liquid A (reaction mix) and 3  $\mu$ l of NC  
134 (ORF1ab/N) PCR reaction liquid B (enzyme), then 5  $\mu$ l of the extracted sample was added to  
135 make the PCRs final volume of 25  $\mu$ l in a PCR plate on a cold block. The PCR tubes were  
136 immediately transferred to an ABI 7500 RT-PCR machine (Applied Biosystems) for detection  
137 of SARS-CoV-2.

138 The probe detection modes were set as: ORF1ab: VIC, Quencher: NONE, N-Gene: FAM,  
139 Quencher: NONE, Internal Control: Cy5, Quencher: NONE, Passive reference: NONE. The  
140 PCR cycle was carried out on the following conditions: 1 cycle of 15 min at 50°C, 1 cycle of  
141 15 min at 95°C, and 45 cycles of 94°C for 15 s and 55°C for 45 s

142 Results were analyzed by 7500 Fast Real Time PCR software version 2.3 to identify SARS-  
143 Cov-2 positive targets by evaluating PCR curves for sigmoidal amplification. A sample was  
144 considered positive for the targeted pathogen when it had cycle threshold (CT) value within  
145 38 cycles ( $Ct < 38$ ), negative extraction blank, positive amplification of ORF1ab, positive  
146 amplification for Positive Control wells and a fluorescence amplification curves for the internal  
147 control well.

148

## 149 **Statistical analyses**

150 Seroprevalence was determined as positivity for either IgG or IgM subtypes over the total  
151 number of individuals tested. The association between SARs-CoV-2 qPCR results, gender,  
152 IgM and IgG was tested using binomial logistic regression analysis. All the statistical analyses  
153 were conducted in STATA Version 16.

## 154 Results

### 155 Demographics

156 A total of 98 participants were recruited into the study, with slightly more females 58.2%  
157 (57/98) than males 41.8% (41/98). The median age was 29 years (interquartile range 19-44)  
158 years. Majority of the participants were symptomatic 73.5% (72/98), reporting multiple  
159 symptoms including history of fever, muscular pain, shortness of breath, headache, and sore  
160 throat amongst others. On severity of symptoms, 6.1 % (6/98) reported mild symptoms with  
161 more than half 57.4% (56/98) reporting severe symptoms. The samples were distributed  
162 equally with 49 from Kisumu County and another 49 from Siaya county.

163

### 164 Seroprevalence

165 During the 3 months' duration from December 2021 to February 2022, the IgG and IgM overall  
166 seroprevalence in 98 symptomatic and asymptomatic individuals in western Kenya was 76.5%  
167 (95% CI =66.9-84.5) and 31.6% (95% CI =22.6- 41.8) respectively. In terms of gender, males  
168 had slightly higher IgG positivity 87.8% (36/41) than females 68.4% (39/57) (Table 1). We  
169 compared the levels of SARS-CoV-2 IgG and IgM antibodies in Kisumu which is largely urban  
170 town and Siaya a more rural set up (Table 1). Whilst the IgG antibodies levels, were almost  
171 similar in the two counties, IgM antibodies were more pronounced in Siaya (40%) than Kisumu  
172 (22%) respectively.

173 Table 1. Demographic characteristics, antibody responses and SARS-COV-2 PCR results  
174 among study participants

<b>Characteristics</b>	<b>Total samples tested</b>	<b>IgG Seroprevalence (95% CI)</b>	<b>IgM Seroprevalence (95% CI)</b>	<b>PCR positivity* (%)</b>
------------------------	-----------------------------	------------------------------------	------------------------------------	----------------------------

<b>Overall</b>	98	76.5% (95% CI =66.9-84.5)	31.6% (95% CI =22.6- 41.8)	32(32.6)
Kisumu County	49	73.5(58.9-85.0)	22.4(11.8-36.6)	12(24.5)
Siaya County	49	79.6(65.7-89.8)	40.8(27.0-55.9)	20(40.8)
<b>Sex</b>				
Female	57	68.4% (54.8-80.1)	24.5(14.1-37.8)	21(36.8)
Male	41	87.8% (36/41)	41.5(26.3-57.9)	11(28.9)
<b>Age group in years</b>				
0-11	6	6.7(2.2-9.5)	3.3(0.4-7.8)	1(16.6)
12-17	18	83.3(58.5-96.4)	27.9(9.7-53.5)	2(11.11)
18-49	52	67.3(52.8-79.7)	28.8(17.1-43.1)	19 (38.0)
50-64	14	92.8(66.1-99.8)	42.9(17.7-71.1)	8(57.14)
>65	8	100(100-1000)	37.5(39.5-71.0)	2(28.6)

175 \*PCR results were only available for 95 participants while serology outcomes were available  
 176 for 98 participants.

177

## 178 Seroprevalence by age

179 To assess immune response to SARS-CoV-2 among asymptomatic and symptomatic  
 180 individuals, we tested for their IgG and IgM antibody levels. We further stratified the individuals  
 181 into several age groups and compared the responses based on gender. Participants aged 18-  
 182 49 years had the highest levels of detectable IgG antibodies from either gender. While all  
 183 adults males aged 50-64 years and those over 65 years were all IgG seropositive, only all  
 184 females aged between 0-11 and adults over 65 years were IgG seropositive (Figure 2).

185

186 **Fig 2. Seroprevalence of infection-induced SARS-CoV-2 IgG antibodies, by gender and**  
187 **age group — Kisumu and Siaya Counties, Kenya, December 2021–March 2022.**

188  
189 The detectable IgM antibodies were highest in participants aged 18-49 years and lowest in  
190 children aged between 0-11 and adults over 65 years though at lower frequency than IgG.  
191 Interestingly, all female participants aged 65 years and above were negative for IgM  
192 antibodies (Figure 3).

193  
194 **Fig 3. Seroprevalence of infection-induced SARS-CoV-2 IgM antibodies, by gender and**  
195 **age group — Kisumu and Siaya Counties, Kenya, December 2021–March 2022.**

196

## 197 **Seroprevalence and vaccination status**

198 Amidst the ongoing vaccination roll-out during the study period almost one third, (30.6% 95%  
199 CI= 21.7-40.7) of the study participants had been fully vaccinated, with close to a quarter  
200 (14.3% 95% CI=8.04-22.8) partially vaccinated. In contrast over half of the study participants  
201 (55.1% 95% CI= 44.7-65.2) had not received any vaccine (Figure 4). When looking at  
202 vaccination status and seroprevalence, out of the 30 fully vaccinated individuals, IgG  
203 seropositivity was 86.7% (95% CI =69.3-96.2) and IgM seropositivity was 40% (95% CI =22.7-  
204 59.4).

205 From the partially vaccinated individuals, IgG seropositivity was 78.6% (95% CI= 49.2-95.3)  
206 with 72.7% (95% CI= 39.0-94.0) IgM seropositivity. Out of the participants that had not been  
207 vaccinated at all, IgG seroprevalence was 70.3% (95% CI 56.4-82.0) with 20.4% (95% CI  
208 10.6-33.5) seropositivity of IgM antibodies.

209 **Fig 4. Vaccination status of the study participants**

210 A binomial logistic regression was run to understand the effects of PCR positivity on the IgG  
211 and IgM seropositivity. SARS-CoV-2 PCR positivity did not significantly predict IgG ( $p = 0.457$   
212 [95% CI 0.514- 4.371]) and IgM ( $p = 0.858$  [95% CI 0.350-2.395]) positivity.

## 213 **Discussion and Conclusions**

214 With the poor uptake of COVID-19 vaccines in African settings amidst the easing of restrictions  
215 on movements and other containment measures, there is need to understand the antibody  
216 responses in the population. The present study aimed to describe the anti-SARs-CoV-2 IgG  
217 and IgM antibody responses during the COVID-19 pandemic in the period between December  
218 2021 and March, 2022 in western Kenya. Generally, we found high levels of IgG and IgM  
219 antibody against SARS-CoV-2 high in the population corroborating recent and previous  
220 findings from population-based surveys in Kenya (11, 14, 15).

221 As previously observed, this was despite the low vaccination rate with only about one third of  
222 the population receiving the full vaccination (16). This implies that most of the population had  
223 been exposed to the COVID-19 virus during this period and had raised antibodies against the  
224 infection. This is suggestive that the population may be heading to herd immunity but this  
225 should not lead to vaccine complacency. It is instructive to note, that the Kenyan government  
226 has prioritized vaccination of the entire population with first and booster doses readily available  
227 in public health facilities.

228  
229 When considering IgG antibody responses and age groups, seroprevalence peaked in adults  
230 aged 18-49 years consistent with other studies in Kenya that reported higher seroprevalence  
231 amongst adults (10). It is plausible that the adults have an expanded immunological memory  
232 driven by their catalog of memory B and T cells (17). Adults older than 65 years of age had a  
233 lower antibody response against the SARS-CoV-2 compared to the other age groups in line  
234 with existing reports (9, 11, 12). Increased comorbidities reported in the older adults may lead  
235 to the aging immune system not mounting a robust response.

236  
237 Interestingly, we recorded a higher seroprevalence of IgM antibodies in Siaya County a more  
238 rural set up compared to Kisumu County a more urbanized town. This was in line with the  
239 (18)higher SARS-CoV-2 RT-qPCR positivity of samples from Siaya county in contrast to

240 Kisumu County during the sample collection period. This finding is consistent with other  
241 studies in Kenya that have reported marked geographic variation in seropositivity (10, 14).  
242 Similar observations of variations in seroprevalence have also been documented across Africa  
243 (19). As the IgM antibody responses are short lived and useful in detecting recent infections  
244 (20), this suggest an ongoing community transmission in Siaya during the study period. The  
245 earlier and robust IgM responses days after onset of symptoms were linked to virus control.  
246 The similar profiles of IgG during the same period in the two counties corroborates its role as  
247 a more persistent antibody (21).

248

249 This study was limited by its recruitment of participants attending the hospitals, as it is possible  
250 that seroprevalence was overestimated due to selection bias. Additionally, the results may not  
251 be generalizable to the whole population as the samples may not have been representative.  
252 Consequently, representative longitudinal studies that follow individuals over a longer time  
253 span are needed to fully understand the SARS-CoV-2 antibody profiles and dynamics.

## 254 **Acknowledgements**

255 We thank the study team for administrative and technical support. We appreciate the support  
256 received from the Kisumu and Siaya Counties health officers during study procedures. We are  
257 grateful to the study participants who took part in the study.

258

259

## 260 References


- 261 1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-  
262 19 in real time. *The Lancet infectious diseases*. 2020;20(5):533-4.
- 263 2. Ciotti M, Ciccozzi M, Terrinoni A, Jiang W-C, Wang C-B, Bernardini S. The  
264 COVID-19 pandemic. *Critical reviews in clinical laboratory sciences*. 2020;57(6):365-  
265 88.
- 266 3. Maeda JM, Nkengasong JN. The puzzle of the COVID-19 pandemic in Africa.  
267 *Science*. 2021;371(6524):27-8.
- 268 4. Bamgboye EL, Omiye JA, Afolaranmi OJ, Davids MR, Tannor EK, Wadee S, et  
269 al. COVID-19 pandemic: is Africa different? *Journal of the National Medical*  
270 *Association*. 2021;113(3):324-35.
- 271 5. Lone SA, Ahmad A. COVID-19 pandemic—an African perspective. *Emerging*  
272 *microbes & infections*. 2020;9(1):1300-8.
- 273 6. Okba NM, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, et al.  
274 Severe acute respiratory syndrome coronavirus 2– specific antibody responses in  
275 coronavirus disease patients. *Emerging infectious diseases*. 2020;26(7):1478.
- 276 7. Post N, Eddy D, Huntley C, van Schalkwyk MC, Shrotri M, Leeman D, et al.  
277 Antibody response to SARS-CoV-2 infection in humans: a systematic review. *PLoS*  
278 *one*. 2020;15(12):e0244126.
- 279 8. Arkhipova-Jenkins I, Helfand M, Armstrong C, Gean E, Anderson J, Paynter  
280 RA, et al. Antibody response after SARS-CoV-2 infection and implications for  
281 immunity: a rapid living review. *Annals of internal medicine*. 2021;174(6):811-21.
- 282 9. Adetifa IM, Uyoga S, Gitonga JN, Mugo D, Otiende M, Nyagwange J, et al.  
283 Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-  
284 19 epidemic in Kenya. *Nature communications*. 2021;12(1):1-6.
- 285 10. Uyoga S, Adetifa IM, Karanja HK, Nyagwange J, Tuju J, Wanjiku P, et al.  
286 Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors.  
287 *Science*. 2021;371(6524):79-82.
- 288 11. Etyang AO, Lucinde R, Karanja H, Kalu C, Mugo D, Nyagwange J, et al.  
289 Seroprevalence of antibodies to severe acute respiratory syndrome coronavirus 2  
290 among healthcare workers in Kenya. *Clinical Infectious Diseases*. 2022;74(2):288-93.
- 291 12. Ngere I, Dawa J, Hunsperger E, Otieno N, Masika M, Amoth P, et al. High  
292 seroprevalence of SARS-CoV-2 but low infection fatality ratio eight months after  
293 introduction in Nairobi, Kenya. *International Journal of Infectious Diseases*.  
294 2021;112:25-34.
- 295 13. Frings M, Lakes T, Muller D, Khan MMH, Epprecht M, Kipruto S, et al. Modeling  
296 and mapping the burden of disease in Kenya. *Sci Rep*. 2018;8(1):9826.
- 297 14. Kagucia EW, Gitonga JN, Kalu C, Ochomo E, Ochieng B, Kuya N, et al.  
298 Seroprevalence of anti-SARS-CoV-2 IgG antibodies among truck drivers and  
299 assistants in Kenya. *medRxiv*. 2021.
- 300 15. Lucinde R, Mugo D, Bottomley C, Aziza R, Gitonga J, Karanja H, et al. Sero-  
301 surveillance for IgG to SARS-CoV-2 at antenatal care clinics in two Kenyan referral  
302 hospitals. *MedRxiv*. 2021.
- 303 16. Stringhini S, Zaballa M-E, Pullen N, Perez-Saez J, de Mestral C, Loizeau AJ,  
304 et al. Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination  
305 campaign in Geneva, Switzerland, 1 June to 7 July 2021. *Eurosurveillance*.  
306 2021;26(43):2100830.

- 307 17. Cox RJ, Brokstad KA. Not just antibodies: B cells and T cells mediate immunity  
308 to COVID-19. *Nature Reviews Immunology*. 2020;20(10):581-2.
- 309 18. Chibwana MG, Jere KC, Kamn'gona R, Mandolo J, Katunga-Phiri V, Tembo D,  
310 et al. High SARS-CoV-2 seroprevalence in health care workers but relatively low  
311 numbers of deaths in urban Malawi. *medRxiv*. 2020.
- 312 19. Rice BL, Annapragada A, Baker RE, Bruijning M, Dotse-Gborgbortsi W,  
313 Mensah K, et al. Variation in SARS-CoV-2 outbreaks across sub-Saharan Africa. *Nat*  
314 *Med*. 2021;27(3):447-53.
- 315 20. Wu J, Liang B, Chen C, Wang H, Fang Y, Shen S, et al. SARS-CoV-2 infection  
316 induces sustained humoral immune responses in convalescent patients following  
317 symptomatic COVID-19. *Nature communications*. 2021;12(1):1-9.
- 318 21. Duysburgh E, Mortgat L, Barbezange C, Dierick K, Fischer N, Heyndrickx L, et  
319 al. Persistence of IgG response to SARS-CoV-2. *The Lancet Infectious Diseases*.  
320 2021;21(2):163-4.
- 321

## 322 **Supporting information captions**

323 Data sets for the study

### A) KENYA



### B) STUDY AREA




Figure 1. Map of the study sites

# IgG antibody responses in males and females by age groups




Figure 2.

# IgM antibody responses by gender and age groups




Figure 3

# Study participants COVID-19 vaccination status




Figure 4